Arsenic Trioxide Combination Chemotherapy In The Treatment Of Relapsed And Refractory Peripheral T-cell Lymphoma Efficacy Analysis

Objective Observation of arsenic trioxide (arsenious acid, AS2O3) combined with chemotherapy efficacy and side effects of treatment of malignant lymphoma.Methods Total9patients,including7males and2females;Age16-74years old, median age was40years.Except for1previously untreated patients,A11patients had previously received first-line chemotherapy. Arsenic trioxide5or10mg/m2, every day, for7-14days.Combination chemotherapy was been used for the past ineffective program.Observed changes in the patient’s condition and toxicity.After two courses according to WHO criteria to evaluate the efficacy and toxicity.Results Nine patients were enrolled in this study.Gross efficiency rate was100%with4cases CR,1cases CRu,2cases PR and2cases SD.Toxic effects can be controlled.Conclusion Arsenic trioxide combined with chemotherapy for patients with relapsed and refractory peripheral T-cell lymphoma had better effective and less toxic effects.